Weekly Analysts’ Ratings Changes for CRISPR Therapeutics (CRSP)

A number of firms have modified their ratings and price targets on shares of CRISPR Therapeutics (NASDAQ: CRSP) recently:

• 11/4/2026 – CRISPR Therapeutics had its price target lowered by Wells Fargo & Company from $75.00 to $70.00. They now have an “equal weight” rating on the stock.
• 11/4/2026 – CRISPR Therapeutics had its price target raised by Citigroup from $88.00 to $90.00. They now have a “buy” rating on the stock.
• 11/3/2026 – CRISPR Therapeutics had its “market outperform” rating reaffirmed by Citigroup.
• 11/3/2026 – CRISPR Therapeutics had its “buy” rating reaffirmed by Needham & Company LLC. They now have a $82.00 price target on the stock.
• 10/15/2026 – CRISPR Therapeutics had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 10/15/2026 – CRISPR Therapeutics is now covered by UBS Group. They set a “neutral” rating and a $52.00 price target on the stock.
• 10/9/2026 – CRISPR Therapeutics had its “buy” rating reaffirmed by HC Wainwright.
• 10/9/2026 – CRISPR Therapeutics had its “buy” rating reaffirmed by UBS Group.
• 9/28/2026 – CRISPR Therapeutics had its “market outperform” rating reaffirmed by Citigroup.
• 9/23/2026 – CRISPR Therapeutics was upgraded by William Blair to “strong-buy”.

CRISPR Therapeutics Price Performance

Shares of NASDAQ CRSP traded up $1.51 during mid-day trading on Friday, reaching $50.07. 1,231,707 shares of the company were exchanged, compared to its average volume of 1,717,527. CRISPR Therapeutics AG has a 52 week low of $44.12 and a 52 week high of $63.45. The company has a quick ratio of 17.85, a current ratio of 16.21 and a debt-to-equity ratio of 0.36. The stock has a market capitalization of $4.86 billion, a PE ratio of -10.56 and a beta of 1.92. The company’s 50 day moving average price is $53.46 and its 200 day moving average price is $52.82.

CRISPR Therapeutics (NASDAQ:CRSP) last issued its quarterly earnings results on Monday, November 2nd. The company reported ($1.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.06) by ($0.09). CRISPR Therapeutics had a negative return on equity of 25.59% and a negative net margin of 1,812.07%. The firm had revenue of $12.67 million for the quarter, compared to the consensus estimate of $14.75 million. The firm’s quarterly revenue was up 1311.1% compared to the same quarter last year. Sell-side analysts forecast that CRISPR Therapeutics AG will post -4.46 earnings per share for the current fiscal year.

Insider Transactions at CRISPR Therapeutics

In related news, General Counsel James R. Kasinger sold 10,400 shares of the business’s stock in a transaction that occurred on Tuesday, September 22nd. The stock was sold at an average price of $60.24, for a total value of $626,496.00. Following the completion of the sale, the general counsel owned 94,784 shares in the company, valued at $5,709,788.16. The trade was a 9.89% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Simeon George sold 14,514 shares of the company’s stock in a transaction that occurred on Wednesday, October 14th. The stock was sold at an average price of $49.63, for a total value of $720,329.82. Following the completion of the sale, the director directly owned 15,486 shares of the company’s stock, valued at approximately $768,570.18. This represents a 48.38% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 93,558 shares of company stock valued at $4,881,663. 5.20% of the stock is currently owned by corporate insiders.

CRISPR Therapeutics AG (NASDAQ: CRSP) is a biotechnology company focused on developing transformative gene-based medicines using CRISPR/Cas9 gene-editing technology. The company’s research programs are designed to address genetic diseases by precisely modifying DNA in cells, with applications across hematology, immunology, oncology, regenerative medicine and cardiovascular disease.

Its lead commercial product is CASGEVY, an autologous cell therapy developed in collaboration with Vertex Pharmaceuticals.